Analyst Consensus ?
ConsensusBuy39 ratings
Bullish2974.4%
Neutral1025.6%
Bearish00.0%
Cigna Corporation · CI · FY2024 Q3 · Calendar Q4 2024
Cigna: Biosimilars and Evernorth support a confident outlook
Cigna’s Q3 analysis supports a constructive operating thesis: Evernorth growth, biosimilar adoption, specialty services, and capital returns provide support, while medical-cost trends and regulatory pressure are the principal counterweights.
Reported Before market openNYSEHealthcare
$81.11B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$7.51
Consensus $7.23
EPS surprise
+3.9%
Reported versus consensus
Reported revenue
$63.69B
Consensus $59.58B
Revenue surprise
+6.9%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+0.6%
Event window
SPY move
-2.0%
Same window
Abnormal move
+2.6%
Stock minus SPY
Volume
2.2×
Versus trailing sessions
Subsequent drift
+7.3%
Up to 20 sessions
CISPY benchmark
Ask FN2 about CI FY2024 Q3
Transcript, numbers and history already loaded
Why did CI rise 0.6% after beating EPS estimates in FY2024 Q3?What changed in CI's guidance and outlook in FY2024 Q3?Give me the bull and bear case for CI after FY2024 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The current analysis adds evidence of accelerating biosimilar activity, continued repurchases, rising technology investment, and a planned Stelara biosimilar launch, while also emphasizing medical-cost pressure and Medicare Advantage disruption.
Guidance delta
Maintained: management reaffirmed its full-year 2024 adjusted EPS guidance and described a positive 2025 EPS-growth outlook.
Key takeaways
- Management described strong Q3 execution, led by Evernorth specialty and care services.
- Biosimilar adoption and the EnCircleRx program were highlighted as important growth drivers.
- The company continues share repurchases while increasing investment in technology platforms.
- Medical-cost pressure, Medicare Advantage disruption, and PBM scrutiny remain key watchpoints.
Management priorities
- Expand biosimilar and specialty-pharmacy offerings.
- Invest in technology, AI-enabled diagnostics, and telehealth platforms.
- Deepen accountable-care and behavioral-health capabilities.
- Continue capital returns alongside planned discretionary capital investment.
Follow CI with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$306.95Current
$225Low
$324.61Average
$415High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 24, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Piper Sandler | Overweight | Overweight | Maintain | Oct 2, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Oct 1, 2026 |
| Jefferies | Hold | Buy | Downgrade | Aug 4, 2026 |
| Raymond James | Outperform | Strong Buy | Downgrade | Aug 3, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Jul 31, 2026 |
| Guggenheim | Buy | Buy | Maintain | Jul 31, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Jul 31, 2026 |
| Bernstein | Outperform | Outperform | Maintain | Jul 9, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jun 8, 2026 |
| UBS | Buy | Buy | Maintain | May 22, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | May 20, 2026 |
| Deutsche Bank | Hold | Buy | Downgrade | May 20, 2026 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | May 1, 2026 |
| Truist Securities | Buy | Buy | Maintain | Feb 17, 2026 |
| TD Cowen | Buy | Buy | Maintain | Feb 9, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Nov 4, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Nov 4, 2025 |
| Baird | Outperform | Outperform | Maintain | Aug 14, 2025 |
| Stephens& Co. | Overweight | Overweight | Maintain | Jan 31, 2025 |
| Stephens & Co. | Overweight | Overweight | Maintain | Jan 31, 2025 |
| Oppenheimer | Outperform | Outperform | Maintain | Jan 31, 2025 |
| Edward Jones | Hold | Buy | Downgrade | Aug 18, 2023 |
| B of A Securities | Buy | Buy | Maintain | Aug 4, 2023 |
| SVB Leerink | Market Perform | Market Perform | Maintain | Feb 8, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | Nov 7, 2022 |
| Loop Capital | Hold | Hold | Maintain | Jun 17, 2022 |
| Cowen & Co. | Outperform | Market Perform | Upgrade | May 9, 2022 |
| Seaport Global | Buy | Buy | Maintain | Nov 17, 2021 |
| BMO Capital | Outperform | Outperform | Maintain | Nov 8, 2021 |
| Citigroup | Buy | Buy | Maintain | Feb 5, 2021 |
| Wedbush | Neutral | Neutral | Maintain | Nov 25, 2020 |
| Susquehanna | Outperform | Neutral | Upgrade | Nov 25, 2020 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | Nov 25, 2020 |
| Sterne Agee CRT | Buy | Neutral | Upgrade | Nov 25, 2020 |
| Sterne Agee | Neutral | Buy | Downgrade | Nov 25, 2020 |
| Monness Crespi Hardt | Buy | Buy | Maintain | Nov 25, 2020 |
| Leerink Swann | Outperform | Outperform | Maintain | Nov 25, 2020 |
| Bank of America | Buy | Buy | Maintain | Nov 25, 2020 |
| Monness, Crespi, Hardt | Neutral | Buy | Downgrade | Nov 5, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $306.95. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Piper Sandler | Analyst unavailable | $387 | $268.88 | +26.1% | Oct 2, 2026 |
| Piper Sandler | Jessica Tassan | $370 | $267.96 | +20.5% | Oct 2, 2026 |
| Jefferies | David Windley | $307 | $282.06 | +0.0% | Aug 4, 2026 |
| Raymond James | Analyst unavailable | $320 | $279.05 | +4.3% | Aug 3, 2026 |
| Robert W. Baird | Analyst unavailable | $362 | $287.66 | +17.9% | Jul 31, 2026 |
| Guggenheim | Analyst unavailable | $361 | $287.66 | +17.6% | Jul 31, 2026 |
| Wells Fargo | Analyst unavailable | $307 | $287.66 | +0.0% | Jul 31, 2026 |
| Bernstein | Analyst unavailable | $381 | $289.73 | +24.1% | Jul 8, 2026 |
| Wolfe Research | Justin Lake | $315 | $293.83 | +2.6% | Jun 16, 2026 |
| Mizuho Securities | Ann Hynes | $340 | $289.48 | +10.8% | Jun 8, 2026 |
| Barclays | Analyst unavailable | $304 | $286.24 | -1.0% | May 26, 2026 |
| UBS | Analyst unavailable | $400 | $282.02 | +30.3% | May 22, 2026 |
| Morgan Stanley | Analyst unavailable | $361 | $291.28 | +17.6% | May 20, 2026 |
| Deutsche Bank | Analyst unavailable | $302 | $291.28 | -1.6% | May 20, 2026 |
| Bernstein | Analyst unavailable | $371 | $279.35 | +20.9% | May 5, 2026 |
| Raymond James | Sarah James | $340 | $285.11 | +10.8% | May 1, 2026 |
| Robert W. Baird | Analyst unavailable | $337 | $285.6 | +9.8% | May 1, 2026 |
| Mizuho Securities | Analyst unavailable | $330 | $285.54 | +7.5% | May 1, 2026 |
| Barclays | Analyst unavailable | $310 | $290.58 | +1.0% | May 1, 2026 |
| Jefferies | Analyst unavailable | $330 | $278.64 | +7.5% | Apr 20, 2026 |
| Truist Financial | Analyst unavailable | $350 | $292.76 | +14.0% | Feb 17, 2026 |
| Deutsche Bank | Analyst unavailable | $304 | $291.17 | -1.0% | Feb 10, 2026 |
| Truist Financial | Analyst unavailable | $338 | $294.2 | +10.1% | Feb 9, 2026 |
| UBS | Analyst unavailable | $375 | $292.84 | +22.2% | Feb 9, 2026 |
| Barclays | Andrew Mok | $303 | $284.53 | -1.3% | Feb 6, 2026 |
| Mizuho Securities | Analyst unavailable | $325 | $283.91 | +5.9% | Jan 9, 2026 |
| Bernstein | Analyst unavailable | $307 | $287.1 | +0.0% | Jan 6, 2026 |
| Truist Financial | Analyst unavailable | $320 | $279.12 | +4.3% | Jan 5, 2026 |
| Barclays | Analyst unavailable | $305 | $279.12 | -0.6% | Jan 5, 2026 |
| Cowen & Co. | Charles Rhyee | $333 | $274.87 | +8.5% | Dec 15, 2025 |
| Guggenheim | Analyst unavailable | $318 | $273.57 | +3.6% | Dec 2, 2025 |
| Bernstein | Analyst unavailable | $294 | $271.57 | -4.2% | Nov 12, 2025 |
| UBS | Analyst unavailable | $294 | $268 | -4.2% | Nov 12, 2025 |
| Wells Fargo | Analyst unavailable | $300 | $264.66 | -2.3% | Nov 5, 2025 |
| Goldman Sachs | Scott Fidel | $330 | $258.62 | +7.5% | Nov 4, 2025 |
| Jefferies | David Windley | $310 | $244.41 | +1.0% | Nov 3, 2025 |
| Morgan Stanley | Erin Wright | $355 | $243 | +15.7% | Oct 31, 2025 |
| Barclays | Analyst unavailable | $300 | $245.1 | -2.3% | Oct 31, 2025 |
| Goldman Sachs | Scott Fidel | $370 | $295.41 | +20.5% | Oct 14, 2025 |
| Wells Fargo | Analyst unavailable | $354 | $302.99 | +15.3% | Oct 7, 2025 |
| Truist Financial | David MacDonald | $375 | $300.72 | +22.2% | Sep 2, 2025 |
| Robert W. Baird | Michael Ha | $372 | $286 | +21.2% | Aug 14, 2025 |
| Deutsche Bank | George Hill | $415 | $270.74 | +35.2% | Aug 5, 2025 |
| Guggenheim | Jason Cassorla | $388 | $333.82 | +26.4% | May 6, 2025 |
| Morgan Stanley | Erin Wright | $390 | $333.01 | +27.1% | May 5, 2025 |
| Barclays | Andrew Mok | $382 | $333.01 | +24.5% | May 5, 2025 |
| Wells Fargo | Stephen Baxter | $341 | $291.46 | +11.1% | Feb 4, 2025 |
| Piper Sandler | Jessica Tassan | $348 | $292.46 | +13.4% | Feb 3, 2025 |
| Raymond James | John Ransom | $360 | $294.21 | +17.3% | Jan 31, 2025 |
| Morgan Stanley | Erin Wright | $379 | $294.21 | +23.5% | Jan 31, 2025 |
| RBC Capital | Ben Hendrix | $355 | $294.21 | +15.7% | Jan 31, 2025 |
| Piper Sandler | Jessica Tassan | $400 | $338.8 | +30.3% | Jun 25, 2024 |
| Robert W. Baird | Michael Ha | $388 | $332.92 | +26.4% | May 29, 2024 |
| Jefferies | David Windley | $407 | $341.5 | +32.6% | May 6, 2024 |
| Oppenheimer | Michael Wiederhorn | $400 | $344.5 | +30.3% | May 3, 2024 |
| Raymond James | Sarah James | $400 | $344.5 | +30.3% | May 3, 2024 |
| RBC Capital | Ben Hendrix | $384 | $344.5 | +25.1% | May 3, 2024 |
| RBC Capital | Ben Hendrix | $354 | $324.06 | +15.3% | Feb 5, 2024 |
| Deutsche Bank | George Hill | $370 | $307.32 | +20.5% | Feb 1, 2024 |
| Leerink Partners | Analyst unavailable | $335 | $289 | +9.1% | Feb 8, 2023 |
| Raymond James | Analyst unavailable | $350 | $288.44 | +14.0% | Feb 7, 2023 |
| Stephens | Analyst unavailable | $370 | $289.12 | +20.5% | Feb 6, 2023 |
| Morgan Stanley | Analyst unavailable | $365 | $301.95 | +18.9% | Jan 6, 2023 |
| Morgan Stanley | Analyst unavailable | $347 | $320.9 | +13.0% | Nov 23, 2022 |
| Raymond James | John Ransom | $370 | $322.13 | +20.5% | Nov 6, 2022 |
| Truist Financial | David MacDonald | $330 | $272.63 | +7.5% | Jul 26, 2022 |
| Jefferies | David Windley | $271 | $273.75 | -11.7% | Jul 14, 2022 |
| Morgan Stanley | Ricky Goldwasser | $296 | $257.6 | -3.6% | Jun 22, 2022 |
| Deutsche Bank | George Hill | $284 | $244.52 | -7.5% | Jun 18, 2022 |
| Mizuho Securities | Ann Hynes | $291 | $263.98 | -5.2% | May 9, 2022 |
| Stephens | Analyst unavailable | $290 | $265.6 | -5.5% | Apr 20, 2022 |
| Truist Financial | David MacDonald | $290 | $254.12 | -5.5% | Apr 11, 2022 |
| Mizuho Securities | Ann Hynes | $266 | $240.51 | -13.3% | Mar 2, 2022 |
| Wells Fargo | Steve Baxter | $278 | $226.47 | -9.4% | Jan 6, 2022 |
| J.P. Morgan | Lisa Gill | $248 | $219.2 | -19.2% | Dec 21, 2021 |
| Goldman Sachs | Nathan Rich | $233 | $215.6 | -24.1% | Dec 14, 2021 |
| UBS | Kevin Caliendo | $244 | $216.63 | -20.5% | Nov 18, 2021 |
| Credit Suisse | A.J. Rice | $300 | $216.05 | -2.3% | Nov 8, 2021 |
| Evercore ISI | Michael Newshel | $230 | $211.09 | -25.1% | Nov 4, 2021 |
| Bank of America Securities | Kevin Fischbeck | $225 | $202.71 | -26.7% | Sep 10, 2021 |
| Cowen & Co. | Gary Taylor | $235 | $211.88 | -23.4% | Sep 9, 2021 |
| Raymond James | John Ransom | $275 | $208.14 | -10.4% | Aug 9, 2021 |
| Stephens | Scott Fidel | $270 | $206.32 | -12.0% | Aug 6, 2021 |
| Barclays | Steven Valiquette | $275 | $206.32 | -10.4% | Aug 6, 2021 |
| Oppenheimer | Michael Wiederhorn | $285 | $206.32 | -7.2% | Aug 6, 2021 |
| Cantor Fitzgerald | Steven Halper | $250 | $203.27 | -18.6% | Aug 5, 2021 |
| Wolfe Research | Justin Lake | $294 | $244.85 | -4.2% | Apr 26, 2021 |
Track every rating change on CI the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationCigna Group, established in 1792 and headquartered in Bloomfield, Connecticut, provides insurance products and related services across the United States. The company operates through two primary segments. Its Evernorth division offers a comprehensive array of coordinated and specialized health solutions, including pharmacy services, benefits administration, care management and delivery, and advanced intelligence solutions. These offerings cater to a diverse clientele, such as health plans, employers, government entities, and healthcare providers.…
Historical context
All CI earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| RDY Dr. Reddy's Laboratories Limited | FY2027 Q2 · Calendar Q4 2026 | +24.0% | -0.2% | Dr. Reddy’s: margins improve as semaglutide rollout advances |
| DGX Quest Diagnostics Incorporated | FY2026 Q3 · Calendar Q4 2026 | +4.5% | +1.8% | Quest Diagnostics: growth broadens, but PAMA remains a headwind |
| ARGX argenx SE | FY2026 Q3 · Calendar Q4 2026 | — | -1.6% | argenx: VYVGART momentum and a broader late-stage pipeline |
| MEDP Medpace Holdings, Inc. | FY2026 Q3 · Calendar Q4 2026 | +9.0% | -1.3% | Medpace: Record awards lift backlog as 2026 outlook improves |
| MOH Molina Healthcare, Inc. | FY2026 Q3 · Calendar Q4 2026 | +12.7% | +0.8% | Molina reaffirms 2026 outlook as Florida contract scales |
Latest beats and misses
Who reports nextBeat on EPS
- FCNCAFY2026 Q3 · October 23, 2026+19.9% EPS+8.2% move
- FCNCNFY2026 Q3 · October 23, 2026+19.9% EPS+0.2% move
- FCNCOFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- FCNCPFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- RDYFY2027 Q2 · October 23, 2026+24.0% EPS-0.2% move
- SLBFY2026 Q3 · October 23, 2026+3.7% EPS+7.1% move
Missed on EPS
- INFYFY2027 Q2 · October 23, 2026-4.8% EPS-6.6% move
- BBDFY2026 Q3 · October 22, 2026-7.7% EPS+3.0% move
- SNAFY2026 Q3 · October 22, 2026-5.9% EPS-3.4% move
- SPOTFY2026 Q3 · October 22, 2026-11.6% EPS+11.1% move
- VRSNFY2026 Q3 · October 22, 2026-2.0% EPS-0.9% move
- HBANMFY2026 Q3 · October 22, 2026-5.3% EPS+0.5% move
Get the CI recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-11-10T18:38:36.707185+00:00
- Polygon adjusted daily market bars · 2026-10-24T21:30:40.734146+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-24T21:30:40.730166+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-24. For educational purposes only; not investment advice.